Clinical Studies

Breast Care
Cardiology
Colon Cancer
Dermatology
Diabetes
Gastrointestinal
HIV/AIDS
Mental Health
Neurology
NeuroOphthalmology
Obesity/Weight Management
Women's Health
Other


Special Features
Advances/Research

 

Efficacy and safety of altretinoin in the treatment of severe chronic hand eczema refractory to topical therapy (IRB #08-179)
Principal Investigator:   Vincent DeLeo, MD
Co-investigators:   Maryann Mikhail, MD
Marcelyn K.Coley, MD
Ramon Solhkhah, MD
Time frame of study:   2.5 years
Time frame of participation:   88 weeks (16 weeks run-in + 24 weeks therapy + 48 weeks follow up)
Number of participants needed:   10
Location of Study:  

Mount Sinai St. Luke's
1090 Amsterdam Avenue
Suite 11D
New York, NY 10025

Contact Name, Number & Email:   Evelyn Koestenblatt
(212) 523-4511
EKoesten@chpnet.org


Summary:
Approximately 600 subjects from 90 centers in the USA will participate in this randomized, double blind, placebo-controlled multicenter study. Once the subject qualifies at the screening they will enter a run-in period of up to 16 weeks. During this time subjects will receive standard skin care and treatment with potent topical corticosteroids. Irritants and allergens will be tested for, identified and avoided by the subject. If subjects are not helped by this treatment, they will be randomized to trial treatment for up to 24 weeks of oral treatment with the study medication.

Criteria for Participation:
- Male and female patients 18 – 75 years old
- Severe, chronic hand eczema lasting over 6 months, refractory to topical therapy.
- Women of childbearing potential must be willing to commit to using 2 effective forms of contraception simultaneously.